In addition, large GWAS metaanalyses have identified polymorphisms in the UMOD promoter that are associated with a lower concentration of uromodulin but higher eGFR (1), a lower risk for CKD, lower blood pressure, a lower risk of hypertension (4), and left atrial remodeling (28). Here, UMOD is linked to hypertensive disorder.